UK: Cytyc's Novasure awaits NICE (National Institute for Clinical Excellence) verdict
This article was originally published in Clinica
Executive Summary
Cytyc has launched its Novasure radiofrequency endometrial ablation system in the UK, as part of plans to expand its EU market coverage of the technology. The impedance-controlled bipolar ablation system used to treat menorrhagia (heavy menstrual bleeding) was CE-marked in 2002, but Novasure's real success in the UK is set to hinge on the current assessment of the technology by the National Institute for Clinical Excellence (NICE).